Resistin is a new adipokine expressed in mouse, rat and human adipose tissue. Resistin may be an important link between obesity and insulin resistance, though this controversial view is complicated by the discovery of multiple sites of resistin expression, including human macrophages, placenta and pancreas. In previous studies we demonstrated that the mouse hypothalamo-pituitary system was also a site of resistin production. Pituitary resistin is developmentally regulated, reduced in the ob/ob mouse and severely down-regulated by food deprivation (24 h). An unexpected finding was that hypothalamic resistin mRNA remained unaffected by fasting. The present experiments examined the localization and possible regulation of hypothalamic resistin protein. Using immunohistochemistry we observed a complex network of resistin+ fibres extending rostrally from the arcuate nucleus of the hypothalamus (ARC) to the preoptic area. Labelled cell bodies occurred only in the ARC and in a periventricular region of the dorsal hypothalamus. Hypothalamic resistin immunoreactivity (ir) was unaffected by fasting (48 h) or by a high fat diet, but the periventricular staining was greatly increased in the lactating mouse. Marked reductions in resistin+ fibres were seen in brain tissue from: (a) ob/ob mice, (b) young mice made underweight for their age by raising them in large litters (20 pups per litter) and (c) mice with hypothalamic lesions induced by monosodium glutamate (MSG) or gold thioglucose (GTG). We speculate that the resistin-ir deficit in genetically obese mice, and in severely underweight mice, could be due to low or absent leptin. In contrast, though MSG- and GTG-treated mice have high levels of circulating leptin, in the presence of excessive visceral fat deposits, we hypothesize that damage to the ARC destroys the resistin+ cell bodies. This latter supposition led us to an additional hypothesis, that resistin-ir would be contained in neurons expressing the proopiomelanocortin (POMC) gene. This proved to be correct. Double label immunofluorescence histochemistry revealed that α-MSH-ir, a marker for POMC neurons, was co-localized with resistin-ir. In conclusion, our data reveal a second example of an adipocytokine co-localized with a hypothalamic neuropeptide. We reported previously that leptin was co-localized with oxytocin and vasopressin. RT-PCR analysis confirmed that resistin mRNA is readily detectable in ARC, but further work is required to determine whether the resistin gene is expressed in POMC neurons or if resistin is specifically accumulated by these cells. Nonetheless, our data suggest that the hypothalamus is a target tissue for resistin.

Keywords:
Gold thioglucose, Monosodium glutamate, Resistin, Melanostimulating hormone, Leptin, Proopiomelanocortin, Mouse, Obesity, Food deprivation, Arcuate nucleus
1.
Wilkinson M, Morash B, Ur E: The brain is a source of leptin. Front Horm Res 2000;26:106–125.
2.
Morash B, Li A, Murphy P, Wilkinson M, Ur E: Leptin gene expression in the brain and pituitary gland. Endocrinology 1999;140:5995–5997.
3.
Wiesner G, Morash BA, Ur E, Wilkinson M: Food restriction regulates adipose-specific cytokines in pituitary gland but not in hypothalamus. J Endocrinol 2004;180:R1–R6.
4.
Morash BA, Ur E, Wiesner G, Roy M, Wilkinson M: Pituitary resistin gene expression: Effects of age, gender and obesity. Neuroendocrinology 2004;79:149–156.
5.
Ahima RS, Flier JS: Leptin. Annu Rev Physiol 2000;62:413–437.
6.
Steppan CM, Lazar MA: The current biology of resistin. J Intern Med 2004;255:439–447.
7.
Baulande S, Lasnier F, Lucas M, Pairault J: Adiponutrin, a transmembrane protein corresponding to a novel dietary- and obesity-linked mRNA specifically expressed in the adipose lineage. J Biol Chem 2001;276:33336–33344.
8.
Kersten S, Mandard S, Tan NS, Escher P, Metzger D, Chambon P, Gonzalez FJ, Desvergne B, Wahli W: Characterization of the fasting-induced adipose factor, a novel peroxisome proliferator-activated receptor target gene. J Biol Chem 2000;275:28488–28493.
9.
Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA: Resistin is expressed in human macrophages and directly regulated by PPAR-γ activators. Biochem Biophys Res Commun 2003;300:472–476.
10.
Yang RZ, Huang Q, Xu A, McLenithan JC, Eisen JA, Shuldiner AR, Alkan S, Gong DW, Eison JA: Comparative studies of resistin expression and phylogenomics in human and mouse. Biochem Biophys Res Commun 2003;310:927–935.
11.
Yura S, Sagawa N, Itoh H, Kakui K, Nuamah MA, Korita D, Takemura M, Fujii S: Resistin is expressed in the human placenta. J Clin Endocrinol Metab 2003;88:1394–1397.
12.
Minn AH, Patterson NB, Pack S, Hoffmann SC, Gavrilova O, Vinson C, Harlan DM, Shalev A: Resistin is expressed in pancreatic islets. Biochem Biophys Res Commun 2003;310:641–645.
13.
Nogueiras R, Gallego R, Gualillo O, Caminos JE, Garcia-Caballero T, Casanueva FF, Dieguez C: Resistin is expressed in different rat tissues and is regulated in a tissue- and gender-specific manner. FEBS Lett 2003;548:21–27.
14.
Hotamisligil GS: The irresistible biology of resistin. J Clin Invest 2003;111:173–174.
15.
Ghosh S, Singh AK, Aruna B, Mukhopadhyay S, Ehtesham NZ: The genomic organization of mouse resistin reveals major differences from the human resistin: Functional implications. Gene 2003;305:27–34.
16.
Gerstmayer B, Kusters D, Gebel S, Muller T, Van Miert E, Hofmann K, Bosio A: Identification of RELM-γ, a novel resistin-like molecule with a distinct expression pattern. Genomics 2003;81:588–595.
17.
Ehrhardt RA, Bell AW, Boisclair YR: Spatial and developmental regulation of leptin in fetal sheep. Am J Physiol 2002;282:R1628–R1635.
18.
Lloyd RV, Jin L, Tsumanuma I, Vidal S, Kovacs K, Horvath E, Scheithauer BW, Couce ME, Burguera B: Leptin and leptin receptor in anterior pituitary function. Pituitary 2001;4:33–47.
19.
Smolinska N, Przala J, Kaminski T, Siawrys G, Gajewska A, Kochman K, Okrasa S: Leptin gene expression in the hypothalamus and pituitary of pregnant pigs. Neuro Endocrinol Lett 2004;25:191–195.
20.
Russo VC, Metaxas S, Kobayashi K, Harris M, Werther GA: Antiapoptotic effects of leptin in human neuroblastoma cells. Endocrinology 2004;145:4103–4112.
21.
Morash BA, Wilkinson D, Ur E, Wilkinson M: Resistin expression and regulation in mouse pituitary. FEBS Lett 2002;526:26–30.
22.
Natarajan M, Wilkinson M: Recovery of hypothalamic NMDA-induced c-fos expression following neonatal glutamate lesions. Brain Res Dev Brain Res 1997;102:97–104.
23.
Seress L: Divergent effects of acute and chronic monosodium L-glutamate treatment on the anterior and posterior parts of the arcuate nucleus. Neuroscience 1982;7:2207–2216.
24.
Bergen HT, Mizuno TM, Taylor J, Mobbs CV: Hyperphagia and weight gain after gold-thioglucose: Relation to hypothalamic neuropeptide Y and proopiomelanocortin. Endocrinology 1998;139:4483–4488.
25.
Engelbregt MJ, van Weissenbruch MM, Popp-Snijders C, Lips P, Delemarre-van de Waal HA: Body mass index, body composition, and leptin at onset of puberty in male and female rats after intrauterine growth retardation and after early postnatal food restriction. Pediatr Res 2001;50:474–478.
26.
Ur E, Wilkinson DA, Morash BA, Wilkinson M: Leptin immunoreactivity is localized to neurons in rat brain. Neuroendocrinology 2002;75:264–272.
27.
Watson RE Jr, Wiegand SJ, Clough RW, Hoffman GE: Use of cryoprotectant to maintain long-term peptide immunoreactivity and tissue morphology. Peptides 1986;7:155–159.
28.
Elias CF, Saper CB, Maratos-Flier E, Tritos NA, Lee C, Kelly J, Tatro JB, Hoffman GE, Ollmann MM, Barsh GS, Sakurai T, Yanagisawa M, Elmquist JK: Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. J Comp Neurol 1998;402:442–459.
29.
Bouret SG, Draper SJ, Simerly RB: Trophic action of leptin on hypothalamic neurons that regulate feeding. Science 2004;304:108–110.
30.
Meister B, Ceccatelli S, Hökfelt T, Anden NE, Anden M, Theodorsson E: Neurotransmitters, neuropeptides and binding sites in the rat mediobasal hypothalamus: Effects of monosodium glutamate lesions. Exp Brain Res 1989;76:343–368.
31.
Khachaturian H, Lewis ME, Schafer MKH, Watson SJ: Anatomy of the CNS opioid systems. Trends Neurosci 1985;8:111–119.
32.
Bing C, Gomez-Ambrosi J, Zabalegui N, Williams G, Trayhurn P: Resistin and RELM-α gene expression in white adipose tissue of lactating mice. Biochem Biophys Res Commun 2002;296:458–462.
33.
Komatsu T, Itoh F, Mikawa S, Hodate K: Gene expression of resistin in adipose tissue and mammary gland of lactating and non-lactating cows. J Endocrinol 2003;178:R1–R5.
34.
Olney JW, Price MT: Excitotoxic amino acids as neuroendocrine probes; in McGeer EG, Olney JW, McGeer PL (eds): Kainic Acid as a Tool in Neurobiology. New York, Raven Press, 1978, pp 239–263.
35.
Debons AF, Krimsky I, Maayan ML, Fani K, Jemenez FA: Gold thioglucose obesity syndrome. Fed Proc 1977;36:143–147.
36.
Zaborszky L, Leranth C, Palkovits M: Gold thioglucose-induced terminal degeneration in mouse hypothalamus. Experientia 1974;30:811–814.
37.
Bouret SG, Draper SJ, Simerly RB: Formation of projection pathways from the arcuate nucleus of the hypothalamus to hypothalamic regions implicated in the neural control of feeding behavior in mice. J Neurosci 2004;24:2797–2805.
38.
Ahima RS, Prabakaran D, Flier JS: Postnatal leptin surge and regulation of circadian rhythm of leptin by feeding. Implications for energy homeostasis and neuroendocrine function. J Clin Invest 1998;101:1020–1027.
39.
Morash B, Wilkinson D, Murphy P, Ur E, Wilkinson M: Developmental regulation of leptin gene expression in rat brain and pituitary. Mol Cell Endocrinol 2001;185:151–159.
40.
Watanobe H, Schioth HB: Postnatal profile of plasma leptin concentrations in male and female rats: Relation with the maturation of the pituitary-gonadal axis. Regul Pept 2002;105:23–28.
41.
Smith JT, Waddell BJ: Developmental changes in plasma leptin and hypothalamic leptin receptor expression in the rat: Peripubertal changes and the emergence of sex differences. J Endocrinol 2003;176:313–319.
42.
Proulx K, Richard D, Walker CD: Leptin regulates appetite-related neuropeptides in the hypothalamus of developing rats without affecting food intake. Endocrinology 2002;143:4683–4692.
43.
Morash BA, Ur E, Wiesner G, Roy J, Wilkinson M: Pituitary resistin gene expression: Effects of age, gender and obesity. Neuroendocrinology 2004;79:149–156.
44.
Herberg L, Leiter EH: Obesity/diabetes in mice with mutations in the leptin or leptin receptor genes. Front Anim Diabet Res 2001;2:63–107.
45.
O’Donohue TL, Miller RL, Jacobowitz DM: Identification, characterization and stereotaxic mapping of intraneuronal α-melanocyte-stimulating hormone-like immunoreactive peptides in discrete regions of the rat brain. Brain Res 1979;176:101–123.
46.
Del Arco A, Peralta S, Carrascosa JM, Ros M, Andres A, Arribas C: Alternative splicing generates a novel non-secretable resistin isoform in Wistar rats. FEBS Lett 2003;555:243–249.
47.
Nohira T, Nagao K, Kameyama K, Nakai H, Fukumine N, Okabe K, Kitano S, Hisatomi H: Identification of an alternative splicing transcript for the resistin gene and distribution of its mRNA in human tissue. Eur J Endocrinol 2004;151:151–154.
48.
Flier JS: Obesity wars: Molecular progress confronts an expanding epidemic. Cell 2004;116:337–350.
49.
Brunetti L, Orlando G, Recinella L, Michelotto B, Ferrante C, Vacca M: Resistin, but not adiponectin, inhibits dopamine and norepinephrine release in the hypothalamus. Eur J Pharmacol 2004;493:41–44.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.